Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06770023 · ClinicalTrials.gov registry record · Phase 1

Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

A Phase 1 study of Pulmonary Hypertension and Lung Transplant, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 1
Development phase
4
Enrollment target
1
Study location

NCT06770023: Recruiting Phase 1 study of Pulmonary Hypertension and Lung Transplant, sponsored by Mayo Clinic.

NCT06770023 is a Phase 1 study of Pulmonary Hypertension and Lung Transplant that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 4 participants, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06770023, a Phase 1 study of Pulmonary Hypertension and Lung Transplant, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.

Primary Outcome

Number of subjects to survive between placement of cannula and lung transplant.

Interventions

  • DEVICE Protek Solo Transseptal Cannula

Study Locations (1)

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2025-12-11
Est. Completion 2028-12
Phase Phase 1
Mayo Clinic

2,844 total trials

What NCT06770023 shows while recruiting

NCT06770023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Protek Solo Transseptal Cannula is the first listed.

NCT06770023 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06770023 about?

NCT06770023 is a clinical study titled "Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension". The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.

What is the current status of trial NCT06770023?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-12-11. Estimated completion is 2028-12.

What conditions does trial NCT06770023 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Lung Transplant.

What interventions are being tested in trial NCT06770023?

The interventions under investigation include: Protek Solo Transseptal Cannula (DEVICE).

Who is sponsoring clinical trial NCT06770023?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06770023 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06770023's enrollment target sits among peer trials

4 73rd of 72 the lowest of 72 other Pulmonary Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06770023, the US trial registry maintained by the National Library of Medicine. NCT06770023 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.